Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can 3D models outperform CT scans in judging pancreatic tumor shrinkage?

NCT ID NCT06582342

Diagnosis Sponsor: Fundación para la Investigación del Hospital Clínico de Valencia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 11, 2026 · Last updated Sep 11, 2026

Summary

Researchers are testing whether a 3D imaging model called 3D-PANC MSP is better than standard CT scans at showing how pancreatic tumors respond to chemotherapy before surgery. The study includes 70 patients with borderline or locally advanced pancreatic adenocarcinoma who have received chemotherapy and are being evaluated for surgery. Doctors will compare the accuracy of both imaging methods against what surgeons actually find during the operation and what pathologists see under the microscope.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
3D imaging technology (3D-PANC MSP model) compared with conventional CT scans
What this could lead to
If the 3D model proves more accurate, doctors could use it to better judge which pancreatic tumors have shrunk enough for surgery after chemotherapy, potentially sparing some patients an operation that is unlikely to help.
What could go wrong
This is a small study of 70 patients at multiple centers, and the 3D model is still being tested against surgery results. It may not prove more accurate than standard CT, and the technology may not be widely available even if it works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2024

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with a diagnosis of borderline or locally advanced PAC of the head of the pancreas who have received neoadjuvant treatment in Spanish hospitals with extensive experience in the treatment of patients with adenocarcinoma of the pancreas and who are part of the pancreatic surgery research group.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: \- Patients with a diagnosis of borderline or locally advanced PAC of the head of the pancreas, as defined by the National Comprehensive Cancer Network (NCCN), who have received neoadjuvant treatment and who undergo surgical exploration with resective intent. Exclusion Criteria: * Patients younger than 18 years of age. * Patients under 18 years of age. * Disease progression during neoadjuvant treatment. * No preoperative CT scan. * Refusal to participate in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adenocarcinoma of the pancreas are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic adenocarcinoma pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adenocarcinoma of the pancreas

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    17 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hospital Carlos Haya

    RECRUITING

    Málaga, Spain

  • Hospital Clínic de Barcelona

    RECRUITING

    Barcelona, Spain

  • Hospital Clínico Universitario de Valencia

    RECRUITING

    Valencia, 46010, Spain

  • Hospital Dr Peset

    RECRUITING

    Valencia, Spain

  • Hospital General de Alicante

    RECRUITING

    Alicante, Spain

  • Hospital General de Castellón

    RECRUITING

    Castellon, Spain

  • Hospital German Trias y Puyol

    RECRUITING

    Barcelona, Spain

  • Hospital Juan XXIII Tarragona

    RECRUITING

    Tarragona, Spain

  • Hospital La Fe

    RECRUITING

    Valencia, Spain

  • Hospital Nuestra señora de la Candelaria

    RECRUITING

    Candelaria, Spain

  • Hospital Son Espases Palma de Mallorca

    RECRUITING

    Palma de Mallorca, Spain

  • Hospital Universitario de Badajoz

    RECRUITING

    Badajoz, Spain

  • Hospital Virgen de la Arrixaca

    RECRUITING

    Murcia, Spain

  • Hospital Virgen de la Victoria

    RECRUITING

    Málaga, Spain

  • Hospital Virgen del Rocío

    RECRUITING

    Seville, Spain

  • Hospital de Bellvitge

    RECRUITING

    Barcelona, Spain

  • Hospital del Mar (Barcelona)

    RECRUITING

    Barcelona, 08003, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.